论文部分内容阅读
目的通过检测Ezrin在正常卵巢上皮和浆液性卵巢癌组织中的差异表达,探讨其对浆液性卵巢癌发生发展的影响。方法收取浆液性卵巢癌冷冻组织40例,正常卵巢上皮27例,提取总RNA,采用Real-time PCR技术检测Ezrin mRNA在两组样本中的表达差异;选取有完整临床病理资料的浆液性卵巢癌石蜡包埋组织134例,以及27例非卵巢癌病例的卵巢上皮组织,通过免疫组织化学染色检测两组样本中Ezrin蛋白质的表达差异,并应用SPSS 20.0软件分析其与临床病理的相关性。结果 Ezrin mRNA在新鲜卵巢癌组织中的表达显著低于正常卵巢上皮组织(P<0.05)。Ezrin蛋白在石蜡包埋卵巢癌组织中也相应降低(P<0.05)。Ezrin蛋白质表达水平与年龄、手术满意程度及化疗敏感程度无相关性,与细胞分化、病理分期及大网膜转移显著相关,(P<0.05)。Ezrin表达水平高的浆液性卵巢癌病例的无进展生存期(PFS)值和总生存期(OS)值都明显高于表达水平低的病例(P<0.05)。但Ezrin并不能作为浆液性卵巢癌的独立预后因素。结论 Ezrin的表达下调与浆液性卵巢癌的发生发展、转移等病理过程相关,其可以作为临床预后的潜在指标。
Objective To detect the differential expression of Ezrin in normal ovarian epithelial and serous ovarian cancers and to explore its effect on the occurrence and development of serous ovarian cancer. Methods Forty cases of serous ovarian cancer and twenty-seven cases of normal ovarian epithelial tissue were collected for total RNA extraction. Real-time PCR was used to detect the expression of Ezrin mRNA in two groups of samples. Serous ovarian cancer with complete clinicopathological data Paraffin-embedded tissues of 134 cases and 27 cases of non-ovarian cancer cases of ovarian epithelial tissue were detected by immunohistochemical staining Ezrin protein differences in the two groups of samples, and SPSS 20.0 software was used to analyze its correlation with clinical pathology. Results The expression of Ezrin mRNA in fresh ovarian cancer tissues was significantly lower than that in normal ovarian epithelial tissues (P <0.05). Ezrin protein was also decreased in paraffin-embedded ovarian cancer (P <0.05). There was no correlation between Ezrin protein expression and age, surgical satisfaction and chemosensitivity (P <0.05), but significant correlation with cell differentiation, pathological stage and omental metastasis (P <0.05). The progression-free survival (PFS) and overall survival (OS) of patients with serous ovarian cancer with high Ezrin expression were significantly higher than those with low expression (P <0.05). However, Ezrin does not serve as an independent prognostic factor for serous ovarian cancer. Conclusion The down-regulation of Ezrin is associated with the development of serous ovarian cancer and the pathological process such as metastasis, which may be used as a potential indicator of clinical prognosis.